New treatment option offers potential to reduce repeat surgeries ...

Please provide your email address to receive an email when new articles are posted on . The FDA based dupilumab’s approval on results from the LIBERTY-AFRS-AIMS trial. This marks the first treatment ...

Patients receiving dupilumab showed clinical improvement in nasal congestion and smell, and were less likely to require systemic corticosteroids or additional sino-nasal surgery. The Food and Drug ...

The FDA approved dupilumab (Dupixent) for treating allergic fungal rhinosinusitis, a first for the condition, the agency announced on Wednesday. Approval stipulates use in individuals 6 years and ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Here are three common causes of sinus infections that aren’t weather-related: Nasal Polyps Nasal polyps are small growths that develop from the nasal tissue that blocks sinus cavities, preventing the ...

Endoscopic sinus surgery for chronic rhinosinusitis (CRS) provides significantly better disease-specific quality of life at 6 months than long-term, low-dose treatment with the macrolide antibiotic ...

ST. LOUIS — A St. Lucian woman can breathe easier tonight thanks in part to a lifesaving surgery performed by doctors at St. Louis University Hospital. Berthia Mason travelled more than 2,500 miles ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a ...